Literature DB >> 32951437

Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya.

Jean de Dieu Tapsoba1, Sahar Z Zangeneh1, Eline Appelmans1, Siavash Pasalar1, Kira Mori1, Lily Peng1, Janice Tao1, Paul Drain2, Gordon Okomo3, Stanley Bii4, James Mukabi5, Stephanie Zobrist6, Martha Brady6, Rael Obanda7, Daniel Oluoch Madiang7, Jane Cover6, Ann Duerr1, Ying Qing Chen1, Christopher Obong'o7.   

Abstract

The Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe (DREAMS) Initiative aims to reduce HIV infections among adolescent girls and young women (AGYW) in Africa. Oral pre-exposure prophylaxis (PrEP) is offered through DREAMS in Kenya to eligible AGYW in high burden counties including Kisumu and Homa Bay. This study examines PrEP persistence among AGYW in high burden community-based PrEP delivery settings. We evaluated PrEP persistence among AGYW in the DREAMS PrEP program in Kisumu and Homa Bay using survival analysis and programmatic PrEP refill data collected between March through December 2017. Among 1,259 AGYW who initiated PrEP during the study period, the median persistence time in the program was 56 days (95% CI: 49-58 days) and the proportion who persisted 3 months later was 37% (95% CI: 34-40%). Persistence varied by county (p < 0.001), age at PrEP initiation (p = 0.002), marital status (p = 0.008), transactional sex (p = 0.002), gender-based violence (GBV) experience (p = 0.009) and current school attendance (p = 0.001) at DREAMS enrollment. Persistence did not vary with orphan status, food insecurity, condom use, age at first sexual encounter or engagement in age-disparate sex at DREAMS enrollment. Targeted strategies are needed to improve AGYW retention in the PrEP program.

Entities:  

Keywords:  Adolescent girls and young women; DREAMS Initiative; HIV prevention; PrEP, survival analysis; persistence

Mesh:

Substances:

Year:  2020        PMID: 32951437      PMCID: PMC7981281          DOI: 10.1080/09540121.2020.1822505

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  33 in total

1.  Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Authors:  Kristine B Patterson; Heather A Prince; Eric Kraft; Amanda J Jenkins; Nicholas J Shaheen; James F Rooney; Myron S Cohen; Angela D M Kashuba
Journal:  Sci Transl Med       Date:  2011-12-07       Impact factor: 17.956

2.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

3.  Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.

Authors:  Nicolette A Louissaint; Ying-Jun Cao; Paul L Skipper; Rosa G Liberman; Steven R Tannenbaum; Sridhar Nimmagadda; Jean R Anderson; Stephanie Everts; Rahul Bakshi; Edward J Fuchs; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-29       Impact factor: 2.205

4.  Long-term persistence with anti-osteoporosis drugs after fracture.

Authors:  C Klop; P M J Welsing; P J M Elders; J A Overbeek; P C Souverein; A M Burden; H A W van Onzenoort; H G M Leufkens; J W J Bijlsma; F de Vries
Journal:  Osteoporos Int       Date:  2015-03-31       Impact factor: 4.507

5.  HIV pre-exposure prophylaxis for women.

Authors:  Anandi N Sheth; Charlotte P Rolle; Monica Gandhi
Journal:  J Virus Erad       Date:  2016-07-01

6.  Defining the HIV pre-exposure prophylaxis care continuum.

Authors:  Amy S Nunn; Lauren Brinkley-Rubinstein; Catherine E Oldenburg; Kenneth H Mayer; Matthew Mimiaga; Rupa Patel; Philip A Chan
Journal:  AIDS       Date:  2017-03-13       Impact factor: 4.177

Review 7.  Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?

Authors:  Gabrielle O'Malley; Gena Barnabee; Kenneth Mugwanya
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

8.  Beyond HIV prevention: everyday life priorities and demand for PrEP among Ugandan HIV serodiscordant couples.

Authors:  Edith Nakku-Joloba; Emily E Pisarski; Monique A Wyatt; Timothy R Muwonge; Stephen Asiimwe; Connie L Celum; Jared M Baeten; Elly T Katabira; Norma C Ware
Journal:  J Int AIDS Soc       Date:  2019-01       Impact factor: 5.396

Review 9.  HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.

Authors:  Connie L Celum; Sinead Delany-Moretlwe; Jared M Baeten; Ariane van der Straten; Sybil Hosek; Elizabeth A Bukusi; Margaret McConnell; Ruanne V Barnabas; Linda-Gail Bekker
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

10.  Evaluating the impact of DREAMS on HIV incidence among young women who sell sex: protocol for a non-randomised study in Zimbabwe.

Authors:  Bernadette Hensen; James R Hargreaves; Tarisai Chiyaka; Sungai Chabata; Phillis Mushati; Sian Floyd; Isolde Birdthistle; Joanna Busza; Frances Cowan
Journal:  BMC Public Health       Date:  2018-01-31       Impact factor: 3.295

View more
  5 in total

1.  Oral PrEP Consultations Among Adolescent Girls and Young Women in Kisumu County, Kenya: Insights from the DREAMS Program.

Authors:  Craig J Heck; Sanyukta Mathur; Habel Alwang'a; Oluoch-Madiang' Daniel; Rael Obanda; Mophine Owiti; Jerry Okal
Journal:  AIDS Behav       Date:  2022-01-31

2.  Evidence for use of a healthy relationships assessment tool in the CHARISMA pilot study.

Authors:  Elizabeth E Tolley; Andres Martinez; Seth Zissette; Thesla Palanee-Phillips; Florence Mathebula; Siyanda Tenza; Miriam Hartmann; Elizabeth T Montgomery
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

Review 3.  Roll-out of HIV pre-exposure prophylaxis: a gateway to mental health promotion.

Authors:  Daniel J Ikeda; Khameer Kidia; Bruce D Agins; Jessica E Haberer; Alexander C Tsai
Journal:  BMJ Glob Health       Date:  2021-12

4.  Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.

Authors:  Yunia Mayanja; Onesmus Kamacooko; Jane Frances Lunkuse; Vincent Muturi-Kioi; Allan Buzibye; Denis Omali; Kundai Chinyenze; Monica Kuteesa; Pontiano Kaleebu; Matt A Price
Journal:  J Int AIDS Soc       Date:  2022-05       Impact factor: 6.707

5.  Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.

Authors:  Ivana Beesham; Dvora L Joseph Davey; Mags Beksinska; Shannon Bosman; Jenni Smit; Leila E Mansoor
Journal:  AIDS Behav       Date:  2022-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.